Frontotemporal dementia and/or amyotrophic lateral sclerosis 1
MONDO:0007105Any frontotemporal dementia with motor neuron disease in which the cause of the disease is a mutation in the C9orf72 gene.
Also known as: ALSFTD, C9ORF72 frontotemporal dementia with motor neuron disease, C9orf72 frontotemporal dementia with motor neuron disease, FTDMND, amyotrophic lateral sclerosis and/or frontotemporal dementia, frontotemporal dementia and/or amyotrophic lateral sclerosis 1, frontotemporal dementia and/or amyotrophic lateral sclerosis type 1, frontotemporal dementia and/or motor neuron disease
26 clinical trials for this condition and its sub-types, 5 tagged with Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Could a common diabetes drug help fight ALS?
Disease control OngoingThis study tests whether metformin, a widely used diabetes drug, is safe for people with a specific genetic form of ALS (C9orf72). Over 24 weeks, 41 participants will take metformin to see if it reduces toxic proteins linked to the disease. The goal is to determine if metformin c…
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a common alcoholism drug help slow ALS? new trial begins
Disease control OngoingThis early-stage study tests the safety of acamprosate, a drug used for alcohol dependence, in 30 adults with ALS who have a specific mutation in the C9orf72 gene. Participants take the pill three times daily for 24 weeks and undergo regular checkups, breathing tests, and spinal …
Phase 1 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a single gene injection slow frontotemporal dementia?
Disease control OngoingThis early-stage trial tests a gene therapy called PBFT02 for frontotemporal dementia (FTD) in people with specific genetic mutations. The therapy delivers a working copy of the GRN gene directly into the brain. The study involves 30 adults and primarily checks for safety and sid…
Phase 1/2 • Sponsor: Passage Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC